Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?
Gilead Sciences reported strong momentum in its HIV business, with flagship drug Biktarvy commanding 53% U.S. market share and injectable PrEP therapy Yeztugo emerging as a key growth driver with $305 million in quarterly sales. The company raised its 2026 HIV sales growth outlook to 12%, supported by strong performances from Biktarvy, Descovy, and Yeztugo. However, aggressive dealmaking and integration costs are pressuring near-term profitability.

